GINWA(SH:600080)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥147,435,488.04, a decrease of 10.34% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was ¥347,660.30, down 96.64% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,603,942.65, a decline of 77.65% compared to the previous year[5] - The basic earnings per share for Q3 2023 was ¥0.0009, a decrease of 96.58% year-on-year[6] - Total operating revenue for the first three quarters of 2023 was CNY 402.81 million, a decrease of 4.5% compared to CNY 423.15 million in the same period of 2022[20] - Net profit for the third quarter of 2023 was CNY 3.39 million, a significant decline of 89.3% compared to CNY 31.83 million in the same quarter of 2022[22] - Basic earnings per share for the third quarter of 2023 were CNY 0.0091, down from CNY 0.0853 in the same quarter of 2022[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,058,831,041.90, an increase of 4.28% from the end of the previous year[6] - Total assets as of the end of the third quarter of 2023 were CNY 2.06 billion, an increase from CNY 1.97 billion at the end of the third quarter of 2022[18] - Total liabilities for the third quarter of 2023 amounted to CNY 371.68 million, up from CNY 290.65 million in the same period of 2022, representing a growth of 28%[18] - The company reported a total non-current asset of CNY 1.20 billion, an increase from CNY 1.03 billion in the previous year[18] - The company’s total equity as of the end of the third quarter of 2023 was CNY 1.69 billion, slightly up from CNY 1.68 billion in the same period of 2022[18] Cash Flow - The company reported a net cash flow from operating activities of -¥11,949,314.66, reflecting a decrease of 28.52% year-to-date[6] - In the first three quarters of 2023, the cash inflow from operating activities was CNY 441,830,298.33, slightly up from CNY 441,329,151.28 in the same period of 2022[23] - The net cash flow from operating activities was negative at CNY -11,949,314.66, compared to CNY -9,297,386.75 in the previous year[23] - The total cash inflow from investment activities was CNY 1,446,976,524.92, significantly higher than CNY 983,848,470.29 in the prior year[24] - The net cash flow from investment activities was CNY -48,514,725.24, a decline from CNY 64,166,189.36 in the same period last year[24] - The cash inflow from financing activities amounted to CNY 175,405,390.44, with a net cash flow of CNY 67,366,210.20, compared to a negative CNY -176,530.76 in the previous year[24] - The total cash and cash equivalents at the end of the period were CNY 439,540,865.47, up from CNY 213,132,731.53 at the end of the same period last year[24] Expenses and Investments - Research and development expenses increased by 37.95% year-to-date, attributed to higher investment in ongoing R&D projects[9] - The company reported a significant decrease in net profit due to increased expenses and reduced investment income, with a year-to-date decline of 89.35%[9] - The company’s financial expenses increased by 58.08% year-to-date, mainly due to higher interest expenses[9] - Research and development expenses increased to CNY 8.86 million in the third quarter of 2023, compared to CNY 6.42 million in the same quarter of 2022, marking a rise of 38.1%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 27.854 million[11] - The largest shareholder, Xing Boyue, holds 19.63% of shares, totaling 73,272,546 shares[11] Strategic Initiatives - The company signed a cooperation agreement to establish the "Western Jinhua Academician Workstation" with Academician Wang Songling's team for drug research and development[13] - The company aims to enhance its technological innovation capabilities through the collaboration with Academician Wang's team[13] - The new drug research project is in the early stages and may be influenced by various factors, with uncertain success[14]